Cytokeratin 5.2 expression as a predictive marker of outcome in patients with acromegaly following endoscopic transsphenoidal surgery
Authors' conclusion
In comparison to DGSA, SGSA presents a decade earlier, are larger in size, more invasive, exhibits higher proliferation, and SSTR5 expression. However, this does not impact post-surgical biochemical and radiological disease control.
Study context
- Population
- Individuals with somatotroph adenomas (acromegaly) undergoing endoscopic transsphenoidal surgery, 2015–2024; median (IQR) age 35.0 (29.0–44.0) years, 56.9% females, 92.2% macroadenoma
- Participants
- 116 individuals
- Exposure
- SGSA vs DGSA histological subtypes of somatotroph adenoma
- SGSAn = 71
- DGSAn = 45reference
- Outcome
- Post-surgical biochemical and radiological disease control
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Post-surgical disease control
- Post-surgical radiological and biochemical disease control rates similar in both groups
- Between SGSA and DGSA: P = 0.707 (NS)
- Between SGSA and DGSA: P = 0.727(NS)
Observational data: associations, not effects.
Further findings
Age at presentation · SGSA presented earlier
P = 0.009
Tumour size · larger with SGSA
P = 0.005
Invasiveness · more invasive with SGSA
P = 0.038
Ki-67 index · more proliferative with SGSA
P < 0.001
| Outcome | DGSA | SGSA | P value |
|---|---|---|---|
| SSTR5 expression (H score)Higher with SGSA | 30.0 H score | 80.0 H score | P = 0.006 |
Original publication
Cytokeratin 5.2 expression as a predictive marker of outcome in patients with acromegaly following endoscopic transsphenoidal surgery. Pituitary. Published 11 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →